Selective Heck reaction of aryl bromides with cyclopent-2-en-1-one or cyclohex-2-en-1-one
摘要:
The selective Heck reaction of cyclopent-2-en-1-one or cyclohex-2-en-1-one with aryl bromides gives a simple access to the corresponding 3-arylcycloalk-2-en-1-ones. The choice of the base was found to be crucial to avoid the formation of 3-arylcyclopentanones or 3-arylcyclohexanones as side-products. Using KF as base, DMF as solvent and Pd(OAc)(2) as catalyst, the target products were obtained in moderate to good yields with a variety of aryl bromides. Substituents such as fluoro, trifluoromethyl, acetyl, benzoyl, formyl, ester or nitrile on the aryl bromide are tolerated. Sterically congested aryl bromides or bromopyridines can also be employed. (C) 2008 Elsevier Ltd. All rights reserved.
Selective Heck reaction of aryl bromides with cyclopent-2-en-1-one or cyclohex-2-en-1-one
作者:Yacoub Fall、Henri Doucet、Maurice Santelli
DOI:10.1016/j.tet.2008.11.006
日期:2009.1
The selective Heck reaction of cyclopent-2-en-1-one or cyclohex-2-en-1-one with aryl bromides gives a simple access to the corresponding 3-arylcycloalk-2-en-1-ones. The choice of the base was found to be crucial to avoid the formation of 3-arylcyclopentanones or 3-arylcyclohexanones as side-products. Using KF as base, DMF as solvent and Pd(OAc)(2) as catalyst, the target products were obtained in moderate to good yields with a variety of aryl bromides. Substituents such as fluoro, trifluoromethyl, acetyl, benzoyl, formyl, ester or nitrile on the aryl bromide are tolerated. Sterically congested aryl bromides or bromopyridines can also be employed. (C) 2008 Elsevier Ltd. All rights reserved.
作者:Mark D. McBriar、Henry Guzik、Ruo Xu、Jaroslava Paruchova、Shengjian Li、Anandan Palani、John W. Clader、William J. Greenlee、Brian E. Hawes、Timothy J. Kowalski、Kim O'Neill、Brian Spar、Blair Weig
DOI:10.1021/jm049035q
日期:2005.4.1
concentrating hormone (MCH) is involved in regulation of food intake and energy homeostasis. Antagonists of the MCH receptor are expected to affect food intake and weight gain, making MCH-R1 an attractive target for obesity treatment. Herein, we report the discovery of a novel, orallyactiveseries of MCH-R1 antagonists that exhibit in vivo efficacy in rodent obesity models.